Conference Call

Graco Inc. will release its Q2 2025 financial results after market close on July 23, 2025. A conference call with leadership will be held on July 24, 2025, featuring a webcast and slide presentation. Both the earnings announcement and webcast replay will be available on investors.graco.com. Graco leads in fluid management technology for industrial and commercial sectors.

Lithia & Driveway (LAD) will announce its second-quarter 2025 financial results before market open on Tuesday, July 29, 2025. A conference call for investors and analysts to discuss the performance will be held the same day at 11:00 a.m. ET. The call can be accessed by dialing (877) 407-8029. A webcast and replay will be available on the company’s investor relations website.

Independent Bank Corporation will release its Q2 2025 earnings on July 24, 2025, around 8:00 a.m. ET, accessible on its website. A conference call will follow at 11:00 a.m. ET with Brad Kessel, Gavin Mohr, and Joel Rahn. Replay details are provided. Independent Bank, with ~$5.3B in assets, offers various financial services across Michigan’s Lower Peninsula.

Worthington Steel, Inc. (NYSE: WS) will release its fiscal fourth-quarter earnings on June 25, 2025, after market close. A conference call will be held on June 26, 2025, at 8:30 a.m. ET to discuss the results. A live webcast will be available on the company’s website. Worthington Steel, a metals processing company, focuses on innovative steel solutions. Conference call ID is 5714141; toll-free dial-in is 888.510.2553.

First BanCorp (FBP) will release its Q2 2025 financial results on July 22, 2025, followed by a conference call and webcast at 10:00 AM ET. The presentation will be accessible via the company’s investor relations website. Replays will be available via telephone and on the website until August 21, 2025, and July 22, 2026, respectively. First BanCorp, through FirstBank Puerto Rico, operates in Puerto Rico, the U.S., British Virgin Islands, and Florida.

Trevi Therapeutics will release topline results from its Phase 2b CORAL trial of Haduvio, an investigational therapy for chronic cough in idiopathic pulmonary fibrosis (IPF). A conference call and webcast will be held on June 2nd, 2025, at 8:30 a.m. ET to discuss the findings. Haduvio targets the cough reflex arc, and initial trials show promising reduction in cough frequency. The results are highly anticipated as there is currently no approved therapy for IPF chronic cough. Further information can be found on the company’s website.